Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

C16G2 Rinse

Small molecule · developed by Armata Pharmaceuticals

Phase 2 Most advanced trial (none active)

ARMP Developer

1 Registered trials

What is C16G2 Rinse?

C16G2 Rinse is a mouth rinse containing 1.6 mg/mL C16G2. It is studied in dental caries.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Oncology
Developer: Armata Pharmaceuticals, Inc. (ARMP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02044081	Phase 2	Dental Caries	Completed	ARMP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dental Caries

More from Armata Pharmaceuticals

AB-PA01 N/A AB-SA01 Phase 1 AP-PA02 Phase 2 AP-SA02 Phase 1/2 C16G2 Phase 2 C16G2 Strip Phase 2

Sources

ClinicalTrials.gov NCT02044081

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARMP page.

Follow ARMP, the company behind C16G2 Rinse

See ARMP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARMP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z